Recent Updates
Recently added Catalysts
TFX Positive Sentiment

Teleflex Reports Third Quarter Financial Results and Full Year 2026 Outlook

Thursday, November 5, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Teleflex Incorporated reported its third quarter 2026 financial results, showing a revenue of $567.8 million, a slight increase of 0.2% from the previous year. The company also reported a significant turnaround in GAAP diluted EPS, rising to $1.30 from a loss of $1.32 in the same quarter last year. Adjusted revenue growth on a pro forma constant currency basis was 3.0%.

Market Sentiment Analysis

POSITIVE FACTORS

  • Revenue increased by 0.2% year-over-year.
  • GAAP diluted EPS improved to $1.30 from a loss of $1.32.
  • Pro forma adjusted constant currency revenue rose by 3.0%.

Full Press Release Details

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the third quarter ended September 30, 2026. Third quarter 2026 continuing operations financial summary1 Revenue from continuing operations of $567.8 million, up 0.2% compared to the prior year period, and up 3.0% on a pro forma adjusted constant currency basis1,2 GAAP diluted EPS from continuing operations of $1.30, compared to $(1.32) in the prior year period Adjusted diluted EP

Frequently Asked Questions

What was Teleflex's revenue for Q3 2026?

Teleflex reported revenue of $567.8 million for Q3 2026.

How much did Teleflex's revenue increase compared to last year?

Revenue increased by 0.2% compared to the prior year.

What was the GAAP diluted EPS for Teleflex in Q3 2026?

The GAAP diluted EPS was $1.30 in Q3 2026.

What was the EPS change from the previous year?

EPS improved from a loss of $1.32 to $1.30.

ShareAdd on Google
Tags: TFX Teleflex Q3 2026 financial results revenue EPS
Last updated: Nov 5, 2026

Biotech snapshot

Cash runway
$327M liquidity · $0M/mo burn
Low dilution risk
Lead asset
Arterial SealingPhase 3
Hemostasis of Arterial Punctures →